PrintBUSINESS DEVELOPMENT
Bridging the Gap on Discovery and Development
Podcast: June 7, 2010The Burrill Report (June 7, 2010): Bridging The Gap on Discovery and Development (.MP3,11.79 Mb)
Bridging the gulf from discovery across what’s become known as the valley of death, remains a problem not only for biopharmaceutical companies, but also for patients in need of new therapies to address unmet medical needs. At a time when raising money for early-stage drug discovery and development remains a challenge, the pharmaceutical industry has been slashing its own R&D spending and increasingly looking beyond its own walls for promising new drugs. We spoke to Paul Laikand, chief business officer for the Sanford-Burnham Medical Research Institute, about how the institute is seeking to establish collaborations with industry, what it's done to exploit the resources it's built, and the unique role independent research institutes can play in addressing the need for translational research.
[Please login to post comments]
- Blaming Genes
Adults are more likely to give too much importance to genetic causes of disease rather than addressing lifestyle, study finds. Read More - Adapting for Success
Video: The BioConference Live interview with G. Steven Burrill from June 3, 2010. Read More - Forest Diabetes Deal
Pharma company gains access to Transtech's new class of compounds in deal that could total $1.1 billion. Read More - Grifols' Taste for Blood
Spanish company offers $3.4 billion for Talecris. Read More - Genzyme and Icahn Reach a Truce
Genzyme says it will appoint two of the activist investor's nominees, and a third endorsed by the company and shareholder. Read More - And the Winners Are...
As the much-watched cancer conference ASCO ends, few stocks get a lift from news at the event. Read More - Developing Cancer
Poorest nation's face a heavier burden from the disease, new global resources shows Read More - Tropical Health – Finding Solutions from Within
By looking inward, Queensland researchers are finding health solutions to tropical disease. Read More - A Coffee Jolt
Study finds no real alertness gained from that morning cup o’ joe. Read More - Amgen’s Bonne Chance
Biotech giant wins earlier-than-expected approval for potential osteoporosis blockbuster. Read More
.gif)
.gif)
- Glaxo’s Revolade Fails to Win Recommendation of U.K. Agency
Bloomberg - Democrats launch push to promote Obama health law
Reuters - Genzyme Says Icahn to Withdraw Slate of Nominees
Bloomberg - Regeneron gout drug works in one trial, fails other
Reuters - Dr. Reddy’s, Cipla May Be Targets, First Global Says
Bloomberg - FDA staff eyes safety of Novartis' MS drug
Reuters - Gates Foundation gives $1.5 bln for women's health
Reuters - Findings May Alter Care for Early Breast Cancer
The New York Times - Nutrition: Study Examines a Diet From TV Ads
The New York Times - Costa Rica puts brakes on popular stem cell tourism
Reuters